Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

Haematologica, Vol 93, Issue 2, e30-e31 doi:10.3324/haematol.12465
Copyright © 2008 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nosari, A.
Right arrow Articles by Montillo, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nosari, A.
Right arrow Articles by Montillo, M.

Online Only Articles

Characteristics and stage of the underlying diseases could determine the risk of opportunistic infections in patients receiving alemtuzumab

A. Nosari, A. Tedeschi, F. Ricci, M. Montillo

Department of Oncology and Haematology, Division of Hematology and Bone Marrow Transplant Unit, Niguarda Ca’ Granda Hospital, Milan, Italy

Correspondence to: A. Nosari, Divisione di Ematologia, Niguarda, Ca’ Granda Hospital, Piazza Ospedale Maggiore 3, 20162, Milan, Italy. Phone: +39-02-64442668. Fax: +39-02-64442033. E-mail: miccaimi{at}tin.it

Alemtuzumab is usually associated with opportunistic infections. We have treated 67 patients, 8 non-Hodgkin’s lymphoma and 59 chronic lymphocytic leukemia (CLL) with campath. Among CLL patients, 6 used alemtuzumab in first line, alone or with chemotherapy, 41 as consolidation therapy and 11 as salvage therapy, 3 alone and 8 with chemotherapy. In our series opportunistic infections were prevalently found in patients submitted to alemtuzumab salvage therapy (33.3%), with or without chemotherapy; in particular 1 pulmonary nocardiosis, 1 tubercolosis. Also during the first line alemtuzumab therapy one case of lysteriosis and one case of HBV reactivation were found (33.3%). No opportunistic infections were diagnosed to our CLL patients in consolidation therapy, when the underlying hematologic disease was reduced or present only as minimal residual disease. A good response of malignancy, namely CLL, to induction therapy, such as a less aggressive schedule of therapy, determine a lower risk of immunosuppression and therefore a low number of opportunistic infections.

Key words: alemtuzumab, opportunistic infections.






HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2008 by the Ferrata Storti Foundation.